Indolent B-Cell Non-Hodgkin Lymphoma — Trials

Indolent B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 172
Recruiting: 85
Ph III recruiting: 4
Growth YoY: +34.6%
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 151–200 of 617 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07492407	CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma	not yet recruiting	—	131	Henan Cancer HospitalOTHER_GOV	0	Mar 25, 2026	clinicaltrials
NCT06793189	MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL	recruiting	Phase 2	145	Ruijin HospitalOTHER	1	Mar 24, 2026	clinicaltrials